Key result
EGFRvIII overexpression markedly accelerates tumor growth and angiogenesis in malignant glioma by inducing Angptl4 expression through the ERK/c-Myc pathway.
Population
LN229 human glioblastoma cell lines and 4-week old female BALB/c nu/nu mice (tumor xenograft model)
Comparison
EGFRvIII overexpression (LN229-vIII) vs Mock or wild-type EGFR overexpression
Design
Preclinical
Follow-up
up to 26 days after tumor implantation
Authors
Loading...
Angptl4 inhibition merits preclinical testing in EGFRvIII gliomas; extends mechanistic data but leaves open clinical translation.
EGFRvIII promotes tumor angiogenesis and growth in malignant gliomas by inducing Angptl4 expression through the ERK/c-Myc pathway.
Katanasaka et al. (2013) studied Malignant glioma. EGFRvIII overexpression vs. Wild-type EGFR or mock transfection was evaluated on Tumor growth and microvessel density. EGFRvIII overexpression markedly accelerates tumor growth and angiogenesis in malignant glioma by inducing Angptl4 expression through the ERK/c-Myc pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: